What's New

Last Posted: Sep 24, 2024

• Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
  Mouhamad Khouja, et al. Leukemia 2024 0
• Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China.
  Ping Yang, et al. Annals of hematology 2024 0
• Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
  Sylvain Carras, et al. Haematologica 2023 0
• Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
  Urban Novak, et al. EClinicalMedicine 2023 0 102221
• Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
  Andrew Ip, et al. Leukemia & lymphoma 2023 0 1-11
• The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study.
  Emanuele Cencini, et al. Leukemia & lymphoma 2023 0 1-9
• Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial.
  Ferrero Simone, et al. Blood advances 2023 0
• MYD88-Mutated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma as a Distinctive Molecular Subgroup Is Associated with Atypical Immunophenotypes in Chinese Patients.
  Mu Yafei, et al. Journal of clinical medicine 2023 0 (7)
• TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
  Obr Aleš, et al. Clinical lymphoma, myeloma & leukemia 2018 0 (11) 762-768
• Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma.
  Wasik Agata M, et al. Blood advances 2018 0 (6) 621-625
• KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
  Ferrero Simone, et al. Haematologica 2019 0 (6) 1604-1612
• Mantle Cell Lymphoma: Which Patients Should We Transplant?
  Gerson James N, et al. Current hematologic malignancy reports 2019 0 (4) 239-246
• The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.
  Zhong Charlie, et al. Leukemia & lymphoma 2019 0 (12) 2899-2908
• TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
  Sakhdari Ali, et al. Annals of diagnostic pathology 2019 0 38-42
• Germline variants of DNA repair genes in early onset mantle cell lymphoma.
  Wang Xiaogan, et al. Oncogene 2020 0 (3) 551-563
• Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
  Streich Lukas, et al. Genes, chromosomes & cancer 2020 0 (8) 484-494
• Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma.
  Annese Tiziana, et al. Translational oncology 2020 0 (3) 100744
• LYmphoid NeXt-Generation Sequencing (LYNX) Panel: A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies.
  Navrkalova Veronika, et al. The Journal of molecular diagnostics : JMD 2021 0 (8) 959-974
• Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
  Rodrigues Joana M, et al. Leukemia & lymphoma 2021 0 (11) 2637-2647
• Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
  Assis-Mendonça Guilherme Rossi, et al. BMC cancer 2021 0 (1) 209
• Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.
  LeBlanc Francis R, et al. Oncotarget 2022 0 986-1002
• Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk.
  Usui Yoshiaki, et al. Cancer science 2022 0 (11) 3972-3979
• Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
  Petrackova Anna, et al. British journal of haematology 2022 0 (3) 371-381
• Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[F]-FDG PET/CT in Elderly Mantle Cell Lymphoma.
  Albano Domenico, et al. Journal of clinical medicine 2022 0 (5)
• Development of a mantle cell lymphoma in an ATM heterozygous woman after occupational exposure to ionising radiation and somatic mutation of the second allele.
  Briani Chiara, et al. Leukemia research 2006 0 (9) 1193-6
• Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research.
  Bertoni Francesco, et al. British journal of haematology 2004 0 (3) 289-98
• Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations.
  Camacho Francisca I, et al. Blood 2003 0 (10) 4042-6
• Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
  Giné Eva, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 0 (11) 1196-1205
• Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma.
  Lisson Catharina Silvia et al. Cancers 2022 14(8)
• Loncastuximab Tesirine: First Approval.
  Lee Arnold, et al. Drugs 2021 6
• Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
  Jeong Seri, et al. Scientific reports 2020 8 (1) 13359
• FDA Approvals Provide Advances for a Range of Cancer Types
  K Honey, AACR Blogs, August 6, 2019
• Aberrant expression of CD10 and BCL6 in mantle cell lymphoma.
  Pizzi Marco, et al. Histopathology 2017 11 (5) 769-777
• A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients.
  Li Xianqian, et al. Medicine 2019 5 (22) e15811
• ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
  Mareckova Andrea, et al. Leukemia & lymphoma 2019 1 1-9
• Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
  Cencini Emanuele, et al. British journal of haematology 2018 9
• A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.
  Bomben Riccardo et al. Haematologica 2018 103(5) 849-856
• Genomic landscape and prognostic analysis of mantle cell lymphoma.
  Yang Ping, et al. Cancer gene therapy 2018 5
• Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
  Zlamalikova Lenka, et al. Oncology reports 2017 8
• Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
  Mbatchi Litaty C, et al. Cancer chemotherapy and pharmacology 2017 7
• Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.
  Onaindia Arantza et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017 Jun
• Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
  Cao Xin-Xin, et al. Annals of hematology 2017 3
• Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP.
  Kim Min Kyeong, et al. Genomics & informatics 2016 12 (4) 205-210
• Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
  Panero Julieta, et al. American journal of hematology 2016 2
• Investigation of Rho-Kinase Expressions and Polymorphisms in Mantle Cell Lymphoma Patients.
  Yanarda? Aç?k Didar, et al. Turkish journal of haematology : official journal of Turkish Society of Haematology 2015 8
• [Correlation of immunoglobulin variable heavy chain gene mutation status with prognosis in patients with mantle cell lymphoma].
  Ji Hong, et al. Zhonghua bing li xue za zhi Chinese journal of pathology 2015 2 (2) 90-4
• Sex- and subtype-specific analysis of H2AFX polymorphisms in non-Hodgkin lymphoma.
  Bretherick Karla L, et al. PloS one 2013 0 (9) e74619
• Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.
  Navarro Alba, et al. Cancer research 2012 10 (20) 5307-16
• Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.
  Kiel Mark J, et al. The Journal of experimental medicine 2012 8 (9) 1553-65
• TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
  Dong Hua-Jie, et al. Medical oncology (Northwood, London, England) 2012 9 (3) 2166-73
• Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
  Halldórsdóttir A M, et al. Leukemia 2011 12 (12) 1904-8
• Mantle cell lymphoma
  From NCATS Genetic and Rare Diseases Information Center
• Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms.
  Galimberti Sara, et al. Leukemia & lymphoma 2011 1 (1) 142-4
• Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.
  Fernberg Pia, et al. Cancer causes & control : CCC 2010 5 (5) 759-69
• Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium.
  Skibola Christine F, et al. American journal of epidemiology 2010 2 (3) 267-76
• Vascular endothelial growth factor polymorphisms in mantle cell lymphoma.
  Galimberti S, et al. Acta haematologica 2010 0 (2) 91-5
• Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.
  Jardin Fabrice, et al. British journal of haematology 2009 9 (6) 607-18
• The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
  Galimberti S, et al. Journal of chemotherapy (Florence, Italy) 2007 6 (3) 315-21
• Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma.
  Novik Karen L, et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007 6 (6) 1098-106
• Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer.
  Wolf Stephan, et al. International journal of cancer. Journal international du cancer 2006 4 (7) 1831-5

More